The molecular product technology provider followed a nine-figure, SoftBank-led round two years ago with a series C led by the corporate's Vision Fund.

SoftBank Vision Fund, the $98.6bn fund formed by telecommunications firm SoftBank, led a $400m series C round for US-based molecular production technology developer Zymergen yesterday Investment banking firm Goldman Sachs, investment manager Hanwha Asset Management and venture capital firms DCVC, DFJ, Innovation Endeavors, True Ventures and Two Sigma Ventures also invested. Zymergen utilises bioengineering, machine…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.